Hansoh Pharma

Update in progress

3692.HK (HKSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Hansoh Pharmaceutical Group Co., Ltd. is a Shanghai-based investment holding company that develops, manufactures, and sells medicines in China. It serves anti-infection, central nervous system, oncology, metabolic, and autoimmune areas, with products such as Ameile, Pulaile, Zefei, Xintai, and Xinyue among others. It has licensing deals with GlaxoSmithKline for ES-SCLC medicines, Biotheus for a bispecific antibody-drug conjugate, and MSD for a GLP-1 receptor agonist.

Company score

Sentiment: 0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive